Please ensure Javascript is enabled for purposes of website accessibility

Who Can Donate Plasma for COVID-19 Patients?

By Brian Orelli, PhD – Jun 14, 2020 at 6:15AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Antibodies of recovered patients can help treat people who are infected with the novel coronavirus.

People who had COVID-19 and are now fully recovered may be eligible to donate plasma to help patients currently infected with COVID-19. Their plasma likely contains antibodies that bind and inhibit SARS-CoV-2, the novel coronavirus that causes COVID-19.

The American Red Cross requires donors to be at least 17 years of age and weigh 110 pounds. Donors who are 17 or 18 have additional weight requirements.

Donors also have to have antibodies that are at a high enough concentration to be helpful for patients. The Food and Drug Administration recommends donors have a SARS-CoV-2 neutralizing antibody titer of 1:160, meaning the antibodies can still be detected even after diluting the sample down to 160th of its original concentration. The agency notes that a titer of 1:80 is acceptable if there aren't any other donated plasma samples with the appropriate blood type available.

Technician looking at donor's plasma

Image source: Getty Images.

The plasma collectors, such as Grifols (GRFS 4.54%), will test for antibody levles, but since the antibody tests are in short supply, the plasma collectors prefer to have donations from people who had a positive diagnosis while they were infected to increase the likelihood that the plasma will have antibodies to SARS-CoV-2. But even without a positive diagnosis, it may be possible to get an antibody test for people who weren't able to get a test while they were symptomatic.

Multiple companies testing plasma-based antibodies

In April, CSL Behring (CSLL.Y 1.82%), Takeda Pharmaceutical (TAK 0.62%), Biotest, Bio Products Laboratory, LFB, and Octapharma joined forces to develop a plasma-derived antibody treatment. Emergent Biosolutions (EBS 0.38%) is also developing multiple plasma-based treatments of its own.

In the long-term, donations of plasma from patients who have recovered from COVID-19 should result in a standardized product that will hopefully help patients recover from COVID-19.

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Emergent BioSolutions. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Emergent BioSolutions Inc. Stock Quote
Emergent BioSolutions Inc.
EBS
$21.07 (0.38%) $0.08
Grifols, S.A. Stock Quote
Grifols, S.A.
GRFS
$6.44 (4.54%) $0.28
Takeda Pharmaceutical Company Limited Stock Quote
Takeda Pharmaceutical Company Limited
TAK
$13.05 (0.62%) $0.08
CSL Limited Stock Quote
CSL Limited
CSLL.Y
$92.91 (1.82%) $1.67

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.